XML 67 R42.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Apr. 30, 2024
Mar. 22, 2024
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2023
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]          
Weighted Average Number of Shares Outstanding, Basic (in Shares)     58,839,868 52,576,258  
Net Income (Loss) Attributable to Parent     $ (13,000) $ (11,506)  
Line of Credit Facility, Current Borrowing Capacity         $ 12,000
Stock Issued During Period, Value, New Issues   $ 3,000 3,027 103  
Proceeds from Issuance of Private Placement     500 0  
Accounts Receivable, after Allowance for Credit Loss     39 107  
Accounts Receivable, Allowance for Credit Loss     24 17  
Cash and Cash Equivalents, at Carrying Value     1,198 3,196  
Inventory, Net     1,540 2,651  
Research and Development Expense     3,773 3,461  
Share Purchase Agreement [Member] | Investor [Member]          
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]          
Stock Issued During Period, Shares, New Issues (in Shares)   8,800,000      
Share Price (in Dollars per share)   $ 0.34      
Subsequent Event [Member]          
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]          
Proceeds from Issuance of Private Placement $ 2,500        
Clinical Trial Inventory [Member]          
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]          
Inventory, Net     $ 392 $ 407